Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research (AACR) Meeting
28. März 2019 08:45 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm and Genomenon to Offer Evidence-Based Genomic Panel Design Service
07. Juni 2018 07:00 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation announced today that it has entered into a co-marketing agreement with Genomenon to offer evidence-based genomic...
Fluidigm Releases Sample Identification Genotyping Panel for Translational and Clinical Research
05. Juni 2018 06:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Advanta™ Sample ID Genotyping Panel for the identification...
Fluidigm to Participate in Upcoming Investor Events
09. Mai 2018 16:05 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative life science company that develops, manufactures and markets multiparameter mass...
Fluidigm Releases CFTR Next-Generation Sequencing Library Prep Assay for Use With the Juno System
12. April 2018 09:29 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Advanta™ CFTR NGS Library Prep Assay, a highly efficient...
Fluidigm Licenses CFTR Next-Generation Sequencing Assay From Baylor Genetics for Use With the Juno System
17. August 2017 16:05 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and Baylor Genetics today announced that they have entered into a licensing agreement to offer a...
Fluidigm Introduces Immuno-Oncology Gene Expression Assay for Translational and Clinical Research
18. Juli 2017 09:00 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 18, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the launch of the Advanta™ Immuno-Oncology Gene Expression Assay, an optimized qPCR...
Fluidigm Introduces New High-Throughput Targeted NGS Library Preparation System
04. August 2016 16:15 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the launch of the Juno™ Targeted DNA Sequencing Library Preparation System, the...